Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350269 · ClinicalTrials.gov registry record · NA
Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates
A NA study, sponsored by Arbor Research Collaborative for Health.
- Terminated
- Registry status
- NA
- Development phase
- 1,310
- Enrollment target
NCT03350269: Clinical Trial NA study, sponsored by Arbor Research Collaborative for Health.
NCT03350269 is a NA study that was terminated before completion, run by Arbor Research Collaborative for Health. The registered enrollment target is 1,310 participants, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03350269, a NA study, was terminated before completion, sponsored by Arbor Research Collaborative for Health.
- TERMINATED
- Registry status
- NA
- Development phase
- 1,310 participants
- Enrollment target
Study Summary
The study is designed as a randomized controlled trial. The investigators hypothesize that kidney transplant recipient candidates whose donors are offered reimbursement of lost wages (treatment arm) will have a higher probability of receiving a living donor kidney transplant than those randomized to no offer of lost wage reimbursement (control arm). The study expects to demonstrate incremental living donor kidney transplants by assisting individuals who wish to be living organ donors but would be otherwise unable to do so due to the obligatory forfeit of income during the evaluation, donation surgery, and post-operative recuperation periods.
Primary Outcome
Number of kidney transplant recipient candidates in intervention vs. control group who receive a living door transplant within one year of their first visit to the participating transplant center for evaluation as a potential kidney transplant recipient (time zero)
Interventions
- OTHER Information provision
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,310 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2020-10-20 |
| Phase | NA |
Why NCT03350269 stopped before completion
NCT03350269 is an interventional study that assigns participants to a tested intervention. Its 1,310 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 1,404-participant average among 58,714 other NA trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Information provision is the first listed.
NCT03350269 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03350269 about?
NCT03350269 is a clinical study titled "Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates". The study is designed as a randomized controlled trial. The investigators hypothesize that kidney transplant recipient candidates whose donors are offered reimbursement of lost wages (treatment arm) will have a higher probability of receiving a living donor kidney transplant than those randomized to...
What is the current status of trial NCT03350269?
This trial is currently terminated. It is a NA study. The enrollment target is 1,310 participants. The study started on 2017-11-15. Estimated completion is 2020-10-20.
What interventions are being tested in trial NCT03350269?
The interventions under investigation include: Information provision (OTHER).
Who is sponsoring clinical trial NCT03350269?
This trial is sponsored by Arbor Research Collaborative for Health, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03350269's enrollment target sits among peer trials
1,310 76th of 2000 higher than 1,925 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI